Literature DB >> 3016095

Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.

T F Tedder, V S Goldmacher, J M Lambert, S F Schlossman.   

Abstract

Epstein Barr virus (EBV) infection of human B lymphocytes is initiated by selective binding of the virus to the C3d receptor (EBV/C3d receptor) on the cell surface and results in polyclonal proliferation of infected cells. In these studies we examined the fate of the EBV/C3d receptor during viral infection by using an immunotoxin made from a monoclonal antibody (HB5) reactive with the receptor and the potent toxin, gelonin. Binding of the HB5-gelonin conjugate to the EBV/C3d receptor before EBV infection (at concentrations as low as 10(-11) M) significantly inhibited the subsequent polyclonal proliferation of virus-infected B lymphocytes. HB5 antibody and gelonin alone did not inhibit proliferation. Because internalization of gelonin-antibody conjugates is required to cause cytotoxicity, these results indicate that infection of B lymphocytes with EBV selectively induced endocytosis of the EBV/C3d receptor with concomitant internalization of the immunotoxin. Proliferation of B lymphocytes that were activated by prior infection with EBV, or activated by cross-linking of their surface immunoglobulin molecules, was not inhibited by the antibody-toxin conjugate even at concentrations as high as 10(-7) M. Also, the growth of B lymphoblastoid cell lines cultured in the presence or absence of infectious EBV was not inhibited by HB5-gelonin. Thus, our results suggest that the EBV/C3d receptor is internalized only during the infection of normal B lymphocytes by EBV, with co-internalization of immunotoxin, and indicate that internalization of the EBV/C3d receptor-immunotoxin complex does not occur simply as a consequence of activation and proliferation of B lymphocytes. The use of a ligand to induce endocytosis of its receptor offers a new strategy for the selective delivery of immunotoxins to cells and may be more generally applicable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Epstein-Barr virus enters B cells and epithelial cells by different routes.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 3.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

Review 4.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

5.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).

Authors:  J D Fingeroth; M L Clabby; J D Strominger
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

8.  Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells.

Authors:  Sarah M Valencia; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 9.  Surface antigens associated with human B cell activation.

Authors:  L K Jung
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

Review 10.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.